← Back to all signals
RESEARCH PAPER ANALYSIS

Impact of Platelet Transfusion at Different Doses in Oncohematology Pediatric Inpatients and Outpatients: A Retrospective Study.

AI interpretation is pending for this paper.

Open original publication →
PMID39834205
JournalPediatric blood & cancer
Publication Date2025-01-20
Ingested2026-08-02 12:03 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Platelet (PLT) transfusion is an essential strategy to prevent bleeding in children with thrombocytopenia associated to cancer treatment. However, data on optimal pediatric dosing and transfusion thresholds are limited. METHODS: This retrospective study analyzed data from 607 pediatric patients with hematologic malignancies, nonmalignant disorders, and solid tumors who developed hypoproliferative thrombocytopenia during therapy. In the first phase (Objective 1), the effective response to transfusion (ERTR) was assessed following International Collaboration for Transfusion Medicine guidelines (ICTMG), comparing low-dose (1.1 × 1011 PLT/m2 body surface area) transfusions for inpatients and medium dose (2.2 × 1011) for outpatients. Transfusion thresholds were set at less than 10,000/µL versus 10,000-20,000/µL, and overall PLT concentrate consumption was analyzed. The second phase (Objective 2) examined the total number of transfusions per patient, incidence of major bleeding events, and bleeding-related mortality rates across dosing groups. RESULTS: ERTR ranged from 65% to 82%, with significantly higher rates in outpatients compared to inpatients. In outpatients with PLT less than 10,000/µL, the medium dose showed no significant advantage over the lower inpatient dose. Similar efficacy was observed between low (<10,000/µL) and high (10,000-20,000/µL) transfusion triggers, with no statistically significant difference in the incidence of major bleeding events across groups. The low-dose strategy was significantly associated with a reduction in PLT volume transfused compared to the standard expected dose. CONCLUSIONS: These findings support the application of ICTMG in pediatric settings. The lower PLT dose for inpatients is safe and effective, providing benefits in resource utilization, while a higher transfusion trigger (20,000/µL) does not improve outcomes.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Clinical features and imaging diagnostic challenges of fetus-in-fetu associated with abdominal cryptorchidism: a case report. BMC pediatrics 49.0 2 [Exploring therapeutic mechanism of Compound Pien Tze Huang Tablets for adenoid hypertrophy in children based on network pharmacology and animal experiments]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 59.39 3 Actinomyces odontolyticus Infection of a Marsupialized Vallecular Cyst in a Two-Month-Old Infant: A Report of a Rare Case. Cureus 47.9 4 Further assessment of structural and social determinant of health effects on breast cancer care timelines: a qualitative study. Frontiers in oncology 61.9 5 Case Report: STAT3 hyper-IgE syndrome in children: two cases report with uncommon complications of tuberculosis and lymphoma. Frontiers in pediatrics 51.4 6 Case Report: Vincristine extravasation managed with amniotic membrane graft in a pediatric patient with Wilms tumor. Frontiers in pediatrics 54.7 7 Epigenetic regulation in medulloblastoma: from tumor heterogeneity to diagnostic, prognostic, and translational applications. Frontiers in molecular neuroscience 60.4 8 Fathers of Children With Cancer: Qualitative Insights and Nursing Implications. Oncology nursing forum 61.4 9 Financial Toxicity Among Family Caregivers of Pediatric, Adolescent, and Young Adult Patients With Cancer: A Qualitative Meta-Synthesis. Oncology nursing forum 60.62 10 Healthcare Access and Utilization in a National Sample of Cancer Survivors With a History of Military Service. Oncology nursing forum 64.0 11 Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide. Journal of inflammation research 42.30 12 The clinical, functional and oncological outcomes of patients with giant cell tumour of bone. A long-term review. Journal of orthopaedic surgery (Hong Kong) 43.40 13 Body composition changes and nutritional challenges in children with acute lymphoblastic leukaemia: Perspectives from low-resource settings. The Indian journal of medical research 58.90 14 Clinical Relevance of Genomics Defined WHO5 Subtypes of Pediatric B-ALL in the Context of Measurable Residual Disease-Directed Risk-Based Therapy. JCO global oncology 63.00 15 Crossing Borders for Pathology Capacity Building in a Regional Setting: A Pediatric Oncology Initiative. JCO global oncology 57.5 16 Recognition and Management of Ulcerative Infantile Hemangioma: Risk Factors, Diagnosis, and Prognosis. Pediatric annals 62.8 17 Inborn Errors of Immunity and Hematopoietic Cell Transplantation: Recognition and Pretransplant Management. Pediatric annals 60.0 18 SLFN11 enhances cisplatin sensitivity in pediatric cancer via activation of stress-response and suppression of survival pathways. British journal of cancer 64.74 19 Phenotypic and genotypic characteristics of pediatric patients with neurofibromatosis type 1: a 12-year single-center cohort study. World journal of pediatrics : WJP 62.5 20 Supportive care needs among patients with breast and cervical cancer at a tertiary cancer treatment center in ethiopia: a cross-sectional study. Scientific reports 36.90 21 Laser interstitial thermal therapy in pediatric neurosurgery: a prospective nationwide study on indications, safety, and early outcomes. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 61.00 22 Pediatric T-cell lymphoblastic lymphoma with t(9;17)(q34;q23)-associated N-terminally truncated NOTCH1 activation: a case report. International journal of hematology 47.9 23 Inflammatory Myofibroblastic Tumor of the Central Airways: Case Report and Review of Diagnostic and Therapeutic Strategies. Case reports in pulmonology 51.14 24 Awareness level of cancer risk factors and warning signs among adults in Mansoura District, Egypt. BMC public health 61.0 25 A Three-Component Immune Framework Stratifies Treatment Response and Escalation in Pediatric Hemophagocytic Lymphohistiocytosis: A Prospective Single-Center Cohort Study. Pediatric blood & cancer 73.80 26 What a wonderful world: beyond relapsed pediatric acute myeloid leukemia. Haematologica 51.12 27 Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome. Haematologica 51.66 28 Pediatric-inspired therapy and blinatumomab consolidation improve outcomes in young adults with Philadelphia-like acute lymphoblastic leukemia. Haematologica 58.90 29 Assessment of testicular function in boys with hematological malignancies: a prospective longitudinal study. The Journal of clinical endocrinology and metabolism 65.2 30 Adverse health outcomes across the life course in individuals with six rare bone diseases: a 10-year population-based cohort study. European journal of endocrinology 57.5 31 Telemedicine in pediatric oncology during the COVID-19 pandemic: a cross-sectional questionnaire-based study evaluating the patient perspective. Pediatric hematology and oncology 65.1 32 Prevalence of hearing loss and tinnitus after childhood cancer treatment: a Danish nationwide registry-based study. Acta oto-laryngologica 40.80
PATIENT-FRIENDLY SUMMARY

Impact of Platelet Transfusion at Different Doses in Oncohematology Pediatric Inpatients and Outpatients: A Retrospective Study.

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic